| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11912-018-0679-9 |
| P698 | PubMed publication ID | 29577208 |
| P2093 | author name string | Christianne Bourlon | |
| Roberta Demichelis-Gómez | |||
| Dennis Lacayo-Leñero | |||
| Sergio I Inclán-Alarcón | |||
| P2860 | cites work | Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies | Q26828511 |
| Adult Acute Lymphoblastic Leukemia | Q30241802 | ||
| Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). | Q34550540 | ||
| Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia | Q35542516 | ||
| How and when should we monitor chimerism after allogeneic stem cell transplantation? | Q35926907 | ||
| Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival | Q36781786 | ||
| Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors | Q36951734 | ||
| Survival of adults with acute lymphoblastic leukemia in Germany and the United States | Q37520582 | ||
| The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. | Q37670062 | ||
| Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis | Q37766527 | ||
| Prognostic factors in adult acute lymphoblastic leukaemia | Q37767265 | ||
| Minimal residual disease monitoring in childhood acute lymphoblastic leukemia | Q38004724 | ||
| Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches | Q38257363 | ||
| Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy | Q38452047 | ||
| Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis | Q38792016 | ||
| Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia? | Q38815331 | ||
| Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. | Q39934787 | ||
| Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. | Q42974471 | ||
| Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia | Q43817166 | ||
| Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. | Q44232638 | ||
| Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia | Q44505579 | ||
| Has MRD monitoring superseded other prognostic factors in adult ALL? | Q45045998 | ||
| Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia | Q45088616 | ||
| In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolid | Q47596252 | ||
| Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia | Q48013821 | ||
| Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia | Q48707792 | ||
| Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. | Q54362486 | ||
| Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. | Q54639337 | ||
| Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? | Q54719477 | ||
| Allogeneic Stem Cell Transplantation in First Complete Remission Enhances Graft-versus-Leukemia Effect in Adults with Acute Lymphoblastic Leukemia: Antileukemic Activity of Chronic Graft-versus-Host Disease | Q62022718 | ||
| Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the P | Q62607764 | ||
| Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival | Q73089005 | ||
| Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial | Q73479481 | ||
| Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation | Q77647316 | ||
| Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison | Q79802931 | ||
| Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia | Q80292597 | ||
| Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies | Q83733166 | ||
| Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy | Q83757805 | ||
| Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL | Q84713730 | ||
| P433 | issue | 4 | |
| P921 | main subject | leukemia | Q29496 |
| lymphoblastic leukemia | Q18553852 | ||
| P304 | page(s) | 36 | |
| P577 | publication date | 2018-03-26 | |
| P1433 | published in | Current Oncology Reports | Q2264969 |
| P1476 | title | Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease. | |
| P478 | volume | 20 |
| Q57468335 | Novel Immunotherapies for T Cell Lymphoma and Leukemia |
| Q101140301 | Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia |
Search more.